was operated at 30 V. The time-of-flight analyzer was operated at a resolution (fwhm) of 30000 at m/z 785 and was calibrated over the m/z range 50−1200 using a 1 µM sodium iodide (NaI) solution (50% v/v acetonitrile solution). To obtain accurate mass measurements, an internal lock-mass correction was applied using leucine enkephalin (m/z 556.2771). Collision induced fragmentation (CID) was performed using an injection voltage of 28 V. Instrument control was performed through the software suite MassLynx, version 4.1.
(1H-benzo[d]imidazol-2-yl)(4-(2-methoxy-3H-imidazo [4,5-b] pyridin-3-yl)phenyl)methanone (2).
Step 1. To a solution of 1H-Benzoimidazole 13 (1.0 g, 8.5 mmol), in 3,4-dihydro-2H-pyran (40 mL) was added catalytic amount of p-toluenesulfonic acid. The reaction mixture was refluxed at 130 0 C overnight. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (200 mL). The organic layer was washed with more water (2 x 100mL), dried over Na 2 SO 4 Step 2. To a solution of 1-(tetrahydro-2H-pyran-2-yl)-1H-benzo[d]imidazole (1.0 g, 4.9 mmol) in THF (13 mL) was added methyl 4-iodobenzoate 14 (1.3 g, 4.9 mmol). The resulting mixture was cooled to -78 0 C. LiHMDS (1.0 mL, 6.2 mmol) was added drop wise while maintaining the internal temperature at -78 0 C. The reaction mixture was allowed to gradually warm to room temperature. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 150 mL). The combined organic layer was dried over Na 2 SO 4 and purified using silica gel to give 0.7 g (33% yield) of the desired product (4-iodophenyl)(1-(tetrahydro-2H-pyran-2-yl)-1H-benzo[d]imidazol-2-yl)methanone 15. Step 3. To a solution of (4-iodophenyl)(1-(tetrahydro-2H-pyran-2-yl)-1H-benzo[d]imidazol-2-yl)methanone 15 (5.0 g, 11.6 mmol) in dimethyl acetamide (25 mL) was added Cs 2 CO 3 (5.6 g, 17.4 mmol) and 3-nitropyridin-2-amine 16 (1.6 g, 11.6 mmol). The reaction mixture was degassed for 15 min before addition of Pd 2 (dba) 3 (0.4 g, 0.4 mmol) and xantphos (0.5 g, 0.9 mmol). The resulting mixture was kept under nitrogen and heated to 100 0 C overnight. The reaction mixture was diluted with water and extracted with EtOAc (300 mL). The organic layer was further washed with water (2 x 50 mL), and purified over silica gel to afford 5.0 g (98% yield) of the desired product (4-((3-nitropyridin-2- Step 4. To a solution of (4-((3-nitropyridin-2-yl)amino)phenyl)(1-(tetrahydro-2H-pyran-2-yl)-
MS (ES+ve)
4 mmol) in ethanol (20 mL) was added molybdenum hexacarbonyl (0.9 g, 3.4 mmol) followed by DBU (1.0 mL, 6.8 mmol). The resulting mixture was heated to 150 0 C for 6 h in a sealed tube. The reaction mixture was evaporated to remove the volatile solvent. Purification by silica gel afforded 1.0 g (77% yield) of desired product (4-((3-aminopyridin-2- Step 5. To a solution of (4-((3-aminopyridin-2-yl)amino)phenyl)(1-(tetrahydro-2H-pyran-2-yl)-
2 mmol) in tetramethyl orthoformate (10 mL) was added catalytic amount of propionic acid. The resulting mixture was refluxed at 100 0 C for 2 h. Volatile solvents were removed by rotovap. The residue was purified by silica gel to give 50 mg (50% yield) Step 6. To the solution of (4-(2-methoxy-3H-imidazo [4,5- General procedures for synthesis of compounds 3-7, 9-12b as illustrated by synthesis of N-(4-(2-ethyl-
Step was used in the next step without further purification.
Step 2. A mixture of N- [4-(3- Step 4. A mixture of N 1 -(5-methylpyridin-2-yl)-N 4 -(3-nitropyridin-2-yl)benzene-1,4-diamine (1 g, 3.1 mmol) and 50% Pd/C (0.5 g) in MeOH (15 mL) was stirred under H 2 at 30 psi for 2 h. Residual
Pd/C was removed by filtration and the filtrate was concentrated to give N 2 -(4-((5-methylpyridin-2-yl)amino)phenyl)pyridine-2,3-diamine (0.8 g, 2.8 mmol, 90% yield) which was used in the next step without further purification.
Step 5 
-(2-((4-((5-methylpyridin-2-yl)amino)phenyl)amino)pyridin-3-
yl)propionamide (120 mg, 0.34 mmol, 50% yield).
Step
The mixture of N-(2-((4-((5-methylpyridin-2-yl)amino)phenyl)amino)pyridin-3-
yl)propionamide (120 mg, 0.3 mmol) and acetic acid (5 mL) was heated to 90 o C for 2 h. The mixture was then concentrated to give the crude product which was purified by column chromatography to af-
The following compounds were prepared according to this general route: Hz, 1H), 4.18 (s, 3H). 
N-(4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)-1H-benzo[d]imidazol-2-amine (3). ESI-1 H-NMR (400MHz,

N-(4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)-5-methylpyridin-2-amine (7). ESI-MS
5-methyl-N-(4-(2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)pyridin-2-amine (10b). ESI-MS
N-(4-(2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)benzo[d]thiazol-2-amine (11a). ESI-MS
N-(4-(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)benzo[d]thiazol-2-amine (12a
N-(3-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)cyclobutyl)benzo[d]thiazol-2-amine (24).
Step Step 4. Step
To a solution of N1-(benzo[d]thiazol-2-yl)cyclobutane-1,3-diamine 28
(255 mg, 1.0 mmol) in DMF (15 mL) was added Na 2 CO 3 (320 mg, 3.0 mmol) and 2-chloro-3-nitro-pyridine 19 (159 mg, 1.0 mmol). The reaction mixture was stirred and heated at reflux overnight. The reaction mixture was then diluted with water (25 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (30 mL), brine (30 mL), dried over Na 2 SO 4 and filtered. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel (20% to 40% Step 7. 
EtOAc/petroleum ether) to give N1-(benzo[d]thiazol-2-yl)-N3-(3-nitropyridin-2-yl)cyclobutane-1,3-
N2-(3-(benzo[d]thiazol-2-ylamino)cyclobutyl)pyridine-2,3-diamine
yl)cyclobutyl)benzo[d]thiazol-2-amine (24a and 24b). N-(3-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-
thiazol-2-amine 24 (800 mg, 2.27 mmol) was separated by chiral prep. HPLC (Column: Chiralcel OD-H 250 x 30 mm, 5u; Mobile phase: 85% hexane in EtOH with 0.05% diethyl amine; Flow rate: 30 mL/min) to give the cis and trans isomers.
Cis isomer N-((1r,3r)-3-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)cyclobutyl)benzo[d]thiazol-
2-amine 24a (0.342 g, 0.97 mmol, 42% yield). Absolute stereospecificity was determined by NOE. Functional inhibition of human recombinant PDE10A was measured as described in the IMAP TR- 
where dQ/dt is the penetration rate of the agent (µm/s), A is the surface area of the cell layer on the Transwell (0.11 cm2), and C0 is the initial concentration of the test compound (µM).
Rat and Human Liver Microsomal Assays.
Liver microsomal stability was measured at 37 °C in phosphate buffer (66.7 mM, pH g) were purchased from Harlan (Harlan, Indianapolis). Rats were group housed on a filtered, forced air isolation rack, and maintained on sterile wood chip bedding in a quiet room on a 12 hour light-dark cycle, with food and water available ad libitum. Animals were allowed for minimum 3 days of adaptation to the laboratory conditions prior to being utilized in the experiments.
LC-MS RO assay with po administration. Sprague Dawley rats were pretreated with vehicle or compound via po dosing. Fifty minutes after dosing, our PDE10A tracer AMG7980 2 was administered by bolus IV injection via lateral tail vein. Ten minutes after tracer injection, animals under isoflurane anesthesia were euthanized by decapitation; samples of blood and brain samples were collected for analysis.
Sample Analysis and Receptor Occupancy Determination. Striatum was used as the target tissue due to high endogenous expression of PDE10A protein, and thalamus was chosen as the reference tissue due to lower expression of PDE10A. Statistical Analysis
